Food Effect on Amelubant Bioavailability in Healthy Volunteers

Phase 1, randomised, open-label trial of amelubant in rheumatoid arthritis (RA) and cystic fibrosis (CF) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum concentration up to 72 hours and Area under the concentration time curve from timepoint zero extrapolated to infinity up to 72 hours. Started Feb 2000; status: completed.